NCT06006169View on ClinicalTrials.gov

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

October 20, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

BL-B01D1

BL-B01D1 was administered by intravenous infusion on D1, D8, or D1 in 3-week cycles.

DRUG

SI-B003

SI-B003 was administered intravenously every 3 weeks (Q3W).

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY